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Abstract
Background: Despite controversy regarding homeopathy, some patients consult homeopaths for depression.
Evidence is required to determine whether this is an effective, acceptable and safe intervention for these patients.
Methods: A pragmatic trial using the “cohort multiple randomised controlled trial” design was used to test the
effectiveness of adjunctive treatment by homeopaths compared to usual care alone, over a period of 12 months
in patients with self-reported depression. One third of patients were randomly selected for an offer of treatment
provided by a homeopath. The primary outcome measure was the Patient Health Questionnaire (PHQ-9) at
6 months. Secondary outcomes included depression scores at 12 months; and the Generalised Anxiety Disorder
(GAD-7) outcome at 6 and 12 months.
Results: The trial over-recruited by 17% with a total of 566 patients. Forty percent took up the offer and received
treatment. An intention-to-treat analysis of the offer group at 6 months reported a 1.4-point lower mean depression
score than the no offer group (95% CI 0.2, 2.5, p = 0.019), with a small standardized treatment effect size (d = 0.30).
Using instrumental variables analysis, a moderate treatment effect size in favour of those treated was found (d = 0.57)
with a between group difference of 2.6 points (95% CI 0.5, 4.7, p = 0.018). Results were maintained at 12 months.
Secondary analyses showed similar results. Similar results were found for anxiety (GAD-7). No evidence suggested any
important risk involved with the intervention.
Conclusion: This trial provides preliminary support for both the acceptability and the effectiveness of treatment by a
homeopath for patients with self-reported depression. Our results provide support for further pragmatic research to
provide more precise estimates of treatment effect.
Trial registration: ISRCTN registry, ISRCTN02484593. Registered on 7 January 2013.
Keywords: Randomised controlled trial, Depression, Anxiety, Homeopathy, Treatment by homeopaths
Background
Depression is a major healthcare challenge in all parts of
the world [1]. World Health Organization (WHO) data
from 60 countries showed a 12 month prevalence of
depressive episodes of 3.2% in patients without comor-
bidities and from 9.3 to 23.0% in those suffering from
chronic healthcare problems [2]. The most commonly
offered interventions include psychological treatment
and antidepressant drugs. The WHO predicts that
depression will become the leading burden of disease by
2030 and it has already become the number one reason
for years lost to disability [1].
Some patients experience partial or no benefit of psy-
chological interventions or pharmacotherapy, or have
experienced or are concerned about side effects of anti-
depressants. Some of these consult homeopaths [3].
Homeopaths provide a combination of consultations and
prescription of homeopathic medicines, guided by
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underlying basic homeopathy principles [4]. Treating
“like with like” is the core principle, stating that sub-
stances causing certain symptoms in healthy persons,
may cure those same symptoms in those who are ill.
There is considerable debate around the use of homeop-
athy, which has a 12-month prevalence of 3.9% (Relton
C, Cooper K, Viksveen P, Fibert P, Harris P, Thomas KJ.
Prevalence of homeopathy use by the general population
worldwide: a systematic review. Homeopathy. Forthcoming
2017 (under review)), in particular the highly diluted
homeopathic medicines, which are produced through
serial dilution and succussion (shaking) to reduce the
risk of side effects. Depression is one of the conditions
homeopaths are most commonly consulted for [5, 6].
An early systematic review found limited evidence
available to assess the effectiveness and safety of hom-
eopathy in depression [7]. Since then, results of two
placebo-controlled trials have been published, suggest-
ing homeopathic medicines may be non-inferior to an
antidepressant and superior to placebo [8, 9]. Although
placebo-controlled trials may be used to assess the
efficacy of medications, they are less suitable to assess
interventions in “real world” practice. Pragmatic trials
assessing the effectiveness of the “whole treatment
package” of interventions, including consultations and
medication, may be of greater relevance to patients,
clinicians and decision makers [10]. Goldacre suggested
unblinded trials comparing visits to a homeopathy
clinic against a General Practitioner’s (GP’s) treatment
as usual might be the way forward for homeopathy
research, as this is of more interest to patients [11].
This is the first pragmatic randomised controlled trial
assessing the effectiveness of treatment provided by
homeopaths for depressed patients.
The primary objective of this trial was to assess the
clinical effectiveness of the offer of adjunctive treatment
provided by homeopaths for patients with self-reported
unipolar depression in addition to usual care, compared
to usual care alone. The secondary objectives were to
assess the effectiveness of received treatment. The accept-
ability and the safety of the intervention were also assessed.
Methods
This pragmatic randomised controlled trial used the
“cohort multiple randomised controlled trial” (cmRCT)
design [12]. One third of all patients with self-reported
depression who were eligible for participation were
randomly selected to receive an offer of treatment pro-
vided by homeopaths as an adjunct to usual care. The
remaining two thirds served as a control group receiving
no offer of treatment and continuing treatment as usual.
Participants were recruited through the Yorkshire Health
Study, a population-based longitudinal observational
cohort [13]. Ethics approval was obtained from the
National Regional Ethics Service (REC reference 12/YH/
0379) and the protocol was published prior to trial start
(ISRCTN02484593) [14]. Data are reported in line with
Additional file 1 [15].
Recruitment
Patients in the Yorkshire Health Study cohort, who had
been recruited through 43 GPs in South Yorkshire, had
previously provided information on their state of health
through a health questionnaire [13]. A mood and health
screening questionnaire was sent to all those who had
previously reported suffering from long-standing depres-
sion or feeling moderately or extremely anxious or
depressed. All adults (age 18–85 years) who responded
to this questionnaire and who fulfilled the inclusion
criteria were included in the trial. Criteria for self-reported
depression included scoring at least 10 points on the
9-item Patient Health Questionnaire (PHQ-9), including
at least 2 points on question 1 (little interest/pleasure in
doing things) or question 2 (feeling down, depressed or
hopeless). PHQ-9 is based on the depression criteria of
the Diagnostic and Statistical Manual of Mental Disorders
(DSM-V). It has been compared to standard screening
criteria and has been found to have a high degree of valid-
ity, reliability, sensitivity and specificity and it is consid-
ered a useful screening tool with a cutoff score for major
depressive disorder of 10 points [16]. Exclusion criteria
were self-reported: Alzheimer’s disease, bipolar disorder,
organic brain damage, schizophrenia, schizoaffective
disorders, other psychotic disorders, or antisocial person-
ality disorder; having received treatment by a homeopath
over the past 3 months; currently being involved in other
health research; or being unable to understand study
questionnaires and accompanying information due to
reduced intellectual capacity, illiteracy or English language
skills. Patients were recruited from 15 September 2013 to
7 February 2014 (randomisation 9 December 2013).
Random selection and consent
One third of the patients who fulfilled the inclusion
criteria were randomly selected to receive an offer of
treatment by a homeopath. Random selection was carried
out by a statistician not otherwise involved in the trial,
using a computer software program, at three time points
(9 December 2013, 14 January 2014 and 7 February 2014)
depending on when patients returned their screening
questionnaire. A simple randomisation process was ap-
plied (no block/stratification randomisation) at a 1:2 ratio.
Only patients’ research ID numbers were provided for the
random selection process. Patients in the cohort had con-
sented to be contacted again and for their data to be used
to assess the benefits of health interventions. Information
about the intervention was sent to patients randomly
selected to receive the offer of treatment and written
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informed consent was obtained from those accepting the
offer, which included consenting to continue standard
medication as prescribed by their GP/specialist.
Blinding
Other than for the random selection process, no blinding
was used due to the pragmatic nature of the research
question “Is treatment by a homeopath effective for
self-reported depression?” No blinding of assessment (stat-
istical analyses) was used, as group allocation would
become obvious due to the 1:2 randomisation ratio.
Trial groups
The intervention was provided by seven homeopaths in
South Yorkshire. As this was a pragmatic trial, practi-
tioners were instructed to practise as they usually do,
and no restrictions were put on the length/frequency of
consultations or medicines they prescribed. They were,
however, provided additional training and guidelines for
reporting risks and adverse events. Treatment was
offered to individual patients for up to 9 months, in
three integrated health clinics in Barnsley, Doncaster
and Sheffield, and in a medical centre in Rotherham. All
patients were free to start or continue any other treat-
ment during the trial.
Outcomes
The primary outcome was the self-report PHQ-9 measure
at 6 months. The PHQ-9 is sensitive to change and useful
for assessing patients with various medical comorbidities
[16]. The secondary outcome measures were PHQ-9 at
12 months; and the Generalized Anxiety Disorder
(GAD-7) outcome measure at 6 and 12 months [17].
The GAD-7 has a high degree of reliability and validity
for measuring anxiety in the general population and in
heterogeneous groups of patients [18]. Both the PHQ-9
and GAD-7 are reported as continuous scores. Two
secondary outcomes included in the study protocol
were removed in order to reduce participant burden
and one (body mass index (BMI)) was removed as there
was no past research suggesting changes in scores
could be expected. Patients were followed up in the
time period from 9 December 2013 to 7 February 2015
(individual patients for 12 months).
Sample size
The trial was designed to test the effectiveness of an
offer of treatment provided by homeopaths as an adjunct
to usual care (offer group), compared to usual care alone
(no offer group). The effect size used for the sample size
calculation was 0.35. Due to the lack of previous prag-
matic trials in this field, the effect size was chosen under
the assumption that a small to moderate effect size should
be the minimum threshold level for recommending the
intervention as an adjunct to usual care. The signifi-
cance level (alpha error) was 0.05 and the power 80%.
The questionnaire non-response rate was estimated to
be 40%. Using an unequal randomisation ratio, this
gave a sample size of 485 patients, with 162 in the offer
group and 323 in the no offer group. A “rolling recruit-
ment” method was used, including patients until a cut-
off date for inclusion.
Statistical methods
Intention-to-treat (ITT) analysis was used to assess the
effectiveness of the offer of treatment provided by a
homeopath as an adjunct to usual care (offer group),
compared to usual care alone (no offer group), for all
patients with analysable data. Patients remained in the
group they were randomly allocated to, irrespective of
whether they received the intervention or not. However,
patients who were found post randomisation not to be
eligible for participation (not fulfilling inclusion/exclusion
criteria) were excluded from the analysis.
A general linear model (GLM) was used for the pri-
mary analysis, comparing the mean depression (PHQ-9)
scores at 6 months post randomisation in the offer group
and no offer groups, and controlling for baseline charac-
teristics. Baseline characteristics were selected using linear
regression as part of a hierarchical model testing the effect
of 11 characteristics considered to potentially influence
depression scores. The 11 characteristics tested were
selected on the basis of the literature on depression re-
search and the opinion of the trial researchers and practi-
tioners. Characteristics with a p value of at least 0.2 were
included in the model.
As the intervention was therapist-based, there could
be clustering or correlation of patients’ outcomes and
treatment offered by particular practitioners. To allow
for this, mean PHQ-9 scores were assessed using gener-
alised estimating equations (GEE) using an exchangeable
correlation to estimate the regression coefficients. Partic-
ipants in the control group were treated as one cluster.
The exchangeable correlation assumed that participant
outcomes within each cluster (practitioner group) had
the same correlation.
At 12 months post randomisation, analysis of covari-
ance (ANCOVA) was applied comparing mean out-
comes in the offer and no offer groups, including
outcomes at 6 and 12 months, and controlling for base-
line characteristics. The influence of baseline character-
istics was tested as for 6-month outcomes. Similar
approaches were used to assess anxiety (GAD-7) scores
at 6 and 12 months. All statistical exploratory tests
were two-tailed with alpha set to 0.05. The 95% confi-
dence interval (CI) for the difference in PHQ-9 scores
was also calculated for all comparisons.
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ITT analyses “water down” any potential effect of
interventions in trials with low acceptance or compli-
ance rates [19]. This is likely to be the case in trials
using the cmRCT design, as patients in the offer group
are only informed about the intervention after being
included in the trial, and a proportion are likely to not
accept the offer of treatment [20]. Moreover, trials in
depression are known to have particular challenges with
recruitment [21]. It was therefore probable that a signifi-
cant proportion of patients would not take up the offer
of treatment. Per-protocol analyses, which are often used
by researchers to assess the effectiveness of treatment
received, carry a high risk of bias. Instead, complier aver-
age causal effect (CACE) analyses have been recom-
mended to take into account non-compliance in RCTs
[22]. In CACE analyses, outcomes in patients who take
up the offer of treatment are compared to outcomes in
the no offer group of patients who would have taken up
the offer had they received it. In this trial, instrumental var-
iables (IV) analysis was used, as this type of CACE-analysis
takes into account patients’ baseline characteristics.
Missing data
Four approaches for dealing with missing data were
used: no imputation for missing data, multiple imput-
ation, regression imputation and last observation carried
forward. Multiple imputation was selected as the primary
method, as it was expected to provide more conservative
results than no imputation for missing data. Little’s missing
completely at random (MCAR) test did not suggest any
systematic patterns in missing data.
Effect size
The standardized effect size was calculated by dividing
the difference in the change of the estimated marginal
mean depression (PHQ-9) scores between the offer and
no offer groups from baseline to 6 months, by the pooled
standard deviation of baseline PHQ-9 scores [23]. Similar
approaches were used for secondary outcomes.
Assessment of acceptability and safety
The acceptability of the intervention was assessed by
calculating the acceptance rate in patients receiving the
offer of treatment. The safety of treatment was assessed
by considering the number and nature of adverse events
and potential risks (suicide, self-harm, causing harm to
others, significant mental deterioration) reported by
patients and practitioners and identified through qualita-
tive interviews carried out by the first researcher. Two
researchers, independently of each other, assessed the
severity and causality of all reported adverse events. For
most adverse events (19/24) the researchers’ assessments
corresponded. All discrepancies in assessments were
resolved through discussion. The severity of adverse
events was assessed using the common terminology
criteria for adverse events. The WHO and Uppsala
Monitoring Centre guidelines were used for assessment
of causality of adverse events.
Results
Recruitment, random selection and questionnaire
response
At the time of recruitment, the Yorkshire Health Study
cohort included 22,179 patients who had consented to
being contacted again. A total of 5740 patients who had
previously reported long-standing depression or feeling
moderately or extremely anxious or depressed were sent
a screening questionnaire (15 September 2013). Out of
these, 2214 (38.6%) returned a completed questionnaire
(7 February 2014), with 566 fulfilling the inclusion
criteria and 185 randomly selected to receive the offer of
treatment (Fig. 1).
At 6 months, 458 patients (81%) returned a follow-up
questionnaire, with 125 (68%) in the offer group and 333
(87%) in the no offer group. Among those in the offer
group who took up the offer of treatment, 88%
responded (n = 65/74), compared to only 54% of those
who did not take up the offer (n = 60/111).
At 12 months, 377 patients (67%) returned a com-
pleted questionnaire, with 72% (n = 274) in the no offer
group and 56% (n = 103) in the offer group. As for the
6-month questionnaires, the proportion of responders in
the offer group was higher among patients who took up
the offer of treatment (n = 58, 78%) than among those
who did not (n = 45, 41%).
Comparability of questionnaire responders and non-
responders
In order to consider the appropriateness of comparing
outcomes of responders in the offer and no offer groups,
which had different response rates, the comparability of
baseline characteristics of responders and non-responders
to the 6-month and 12-month questionnaires in the offer
and no offer groups was assessed using a multiple linear
regression model.
No evidence was found suggesting there were signifi-
cant differences in depression or anxiety scores at base-
line between responders and non-responders to the
6-month and 12-month questionnaires in the offer and
the no offer groups (data not shown). At 6 months, sta-
tistically significant differences (≤0.05) were found in 5
of 20 baseline characteristics (age, employment status,
deprivation score, existence of more than three long-
standing conditions and the proportion of patients report-
ing whether they were using antidepressants), but none
were considered likely to significantly influence 6-month
outcomes. At 12 months, the only statistically significant
differences in baseline characteristics included lower
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likelihood of non-responders in the offer group reporting
the time of onset of their depression and lower likelihood
of reporting whether they had used antidepressants in the
past. It was considered to be unlikely that this would influ-
ence 12-month outcomes. Furthermore, no statistically
significant differences in baseline characteristics were
found between patients in the offer group who received
the intervention and those who did not (data not shown).
Statistical analyses of the outcomes in the offer and no
offer groups at 6 and 12 months could therefore be car-
ried out with limited risk of significant influence of any
known potential confounding due to differences in the
response rates.
Baseline characteristics
The trial included patients of all age groups ranging
from 18 to 85 years (mean 55 years, SD 15). The major-
ity were female (61%) and of British ethnic origin (96%).
Fewer were employed (38%) than not (56%), and over
60% were among the most (42%) and second most (19%)
deprived quintiles of patients. Depression, anxiety and
other baseline characteristics were comparable in the
offer and no offer groups (Tables 1, 2 and 3).
The patients’ mean depression score was 17.0 (SD 4.6),
measured on the 0–27 point self-report PHQ-9. A
slightly larger proportion suffered from moderate (35%)
and moderately severe (36%) depression, than severe
(30%) depression. Over 90% of patients reporting on when
their depression first started (n = 391, 69%), could be cate-
gorised as suffering from chronic self-reported depression
(lasting a minimum of 1 year), and 70% had suffered from
depression for at least 5 years. The onset of the current
depression episode was only reported by 40% (n = 227),
and among these patients over 60% suffered from a
chronic depression episode (minimum of 1 year).
The average anxiety score, measured using the self-
report GAD-7 outcome measure (range 0–21), was 13.7
(SD 4.8), with 80% suffering from moderate (34%) or
severe (46%) anxiety. More than 90% reported suffering
from at least one long-standing condition, with an aver-
age of 3.0 (SD 1.8) long-standing conditions. The mean
BMI score was 28.2 (SD 6.6), with 56% being overweight
(24%), obese (26%) or morbidly obese (6%).
Four in ten patients were taking antidepressant drugs,
and 60% had done so in the past. On average, patients
were taking 4.7 (SD 3.9) different drugs. The most com-
monly used healthcare practitioners/services over the
past 3 months were GPs (mean 2.6 consultations, SD
3.8), nurses (1.6, SD 4.0) or hospital outpatient services
(1.3, SD 2.2) (Table 3). The use of mental health workers
(0.7, SD 2.2), counsellors (0.7, SD 2.6) and psychothera-
pists (0.4, SD 1.5) was less common (data not shown).
Fig. 1 Consolidated standards of reporting trials (CONSORT) flow-diagram: recruitment, randomisation and flow of patients
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Higher depression scores were significantly correlated
with higher anxiety scores (p < 0.01), greater numbers
of long-standing conditions (p < 0.001) and higher BMI
scores (p = 0.010). There was no correlation between de-
pression scores and current antidepressant use (p = 0.511),
but there was correlation between depression scores
and greater use of GPs (p = 0.003), mental health
workers (p = 0.001) and counsellors (p = 0.009).
Although patients in our trial were more likely to suf-
fer from chronic depression and the non-British ethnic
population was underrepresented, baseline characteris-
tics were overall comparable to other studies. As in our
trial, other studies have shown that depression is more
common in women [24] and in populations with higher
unemployment [25] and lower socio-economic status
[26]. Anxiety is the most common comorbidity [27] and
it is also correlated witho obesity [28].
The intervention
Over the 12 months of the trial, the 74 patients who took
up the offer of treatment received a total of 490 consulta-
tions with a homeopath, with a median of 7.5 (interquar-
tile range 4.8–9.0) consultations over 6.5 months (IQR
4.1–8.9). Consultations lasted a median of 57 minutes
(IQR 48–65) and 526 prescriptions (median per patient
7.0, IQR 4.0–9.3) of 68 different homeopathic medicines
were made. In 18% of consultations, patients received add-
itional advice, such as recommendations to make dietary
changes (e.g. reduce sugar/fat intake), to consult with
other practitioners (mostly GPs), initiate self-care mea-
sures (e.g. stress-reducing exercises), or use various other
products (e.g. supplements or herbal teas). No patient was
recommended St. John’s Wort, a herb commonly used in
the treatment of depression.
Acceptability
Of 185 patients, 74 (40%) took up the offer of treatment
and had at least one consultation with a homeopath.
Out of these patients, 90.5% (n = 67) had more than one
consultation, 75.7% (n = 56) had 5–12 consultations,
whereas 9.5% (n = 7) only had one consultation.
Effectiveness in the offer group
Depression outcomes and estimation
The primary analysis showed a mean between-group
difference in depression (PHQ-9) scores in favour of the
offer group at 6 months of 1.4 points (95% CI 0.2, 2.5,
p = 0.019), suggesting a small standardized effect size in
the offer group (Cohen’s d = 0.30). Results were main-
tained at 12 months (ANCOVA: mean difference 1.4
points, 95% CI 0.3, 2.5, p = 0.015, Cohen’s d = 0.30).
Secondary analyses at 6 and 12 months were comparable
to the main analysis, although 3 out of 31 tests were not
statistically significant (details in Additional files).
Anxiety outcomes and estimation
The primary analysis of the anxiety (GAD-7) outcome
measure showed a mean between-group difference in
Table 1 Baseline characteristics
Baseline characteristics Offer group (n = 185) No offer group (n = 381) Total (n = 566)
Age (years) (mean, SD) 55.8 (15.0) 53.9 (14.4) 54.5 (14.6)
Female 114 (61.6) 229 (60.1) 343 (60.6)
Children ≤2 years 9 (4.9) 14 (3.9) 24 (4.2)
Pregnant 0 (0.0) 4 (1.0) 4 (0.7)
Ethnicity:
British 179 (96.8) 364 (95.5) 543 (95.9)
Non-British 6 (3.2) 15 (3.9) 21 (3.7)
Unknown 0 (0.0) 2 (0.5) 2 (0.4)
Employed:
Yes 64 (34.6) 152 (39.9) 216 (38.2)
No 111 (60.0) 209 (54.9) 320 (56.5)
Unknown 10 (5.4) 20 (5.2) 30 (5.3)
Index of Multiple Deprivation (IMD) quintile:
1 (least deprived) 11 (5.9) 21 (5.5) 32 (5.7)
2 34 (18.4) 76 (19.9) 110 (19.4)
3 26 (14.1) 55 (14.4) 81 (14.3)
4 34 (18.4) 73 (19.2) 107 (18.9)
5 (most deprived) 80 (43.2) 156 (40.9) 236 (41.7)
Figures are frequencies (percentages) unless stated otherwise
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Table 2 Baseline health measures
Baseline health measures Offer group (n = 185) No offer group (n = 381) Total (n = 566)
PHQ-9 score (mean, SD) 16.9 (4.5) 17.0 (4.6) 17.0 (4.6)
PHQ-9 category:
Moderate (10–14 points) 64 (34.6) 133 (34.9) 197 (34.8)
Moderately severe (15–19 points) 69 (37.3) 133 (34.9) 202 (35.7)
Severe (20–27 points) 52 (28.1) 115 (30.2) 167 (29.5)
Depression onset:
Acute (<3 months) 2 (1.1) 4 (1.0) 6 (1.1)
Sub-acute (3 months– < 1 year) 5 (2.7) 14 (3.7) 19 (3.4)
Chronic (short) (1– < 2 years) 12 (6.5) 39 (10.2) 51 (9.0)
Chronic (long) (2– < 5 years) 10 (5.4) 31 (8.1) 41 (7.2)
Chronic (very long) (5 years +) 89 (48.1) 185 (48.6) 274 (48.4)
Chronic (any) 111 (60.0) 255 (66.9) 366 (64.7)
Unknown 67 (36.2) 108 (28.3) 175 (30.9)
Depression episode onset:
Acute (<3 months) 10 (5.4) 24 (6.3) 34 (6.0)
Sub-acute (3 months– < 1 year) 8 (4.3) 25 (6.6) 33 (5.8)
Periodic 3 (1.6) 14 (3.7) 17 (3.0)
Chronic (short) (1– < 2 years) 9 (4.9) 13 (3.4) 22 (3.9)
Chronic (long) (2– < 5 years) 8 (4.3) 11 (2.9) 19 (3.4)
Chronic (very long) (5 years+) 9 (4.9) 13 (3.4) 22 (3.9)
Chronic (unspecified) 30 (16.2) 46 (12.1) 76 (13.4)
Chronic (any) 56 (30.3) 83 (21.8) 139 (24.6)
None (patient’s opinion) 1 (0.5) 3 (0.8) 4 (0.7)
Unknown 107 (57.8) 232 (60.9) 343 (60.6)
GAD-7 score (mean, SD) 13.4 (4.8) 13.8 (4.8) 13.7 (4.8)
GAD-7 category:
Normal (0–4 points) 6 (3.2) 14 (3.7) 20 (3.5)
Mild (5–9 points) 32 (17.3) 59 (15.5) 91 (16.1)
Moderate (10–14 points) 68 (36.8) 126 (33.1) 194 (34.3)
Severe (15–21 points) 78 (42.2) 181 (47.5) 259 (45.8)
Unknown 1 (0.5) 1 (0.3) 2 (0.4)
BMI score (mean, SD) 28.3 (6.6) 28.1 (6.6) 28.2 (6.6)
BMI category:
Underweight (<18.5) 3 (1.6) 8 (2.1) 11 (1.9)
Healthy weight (18.5–24.9) 58 (31.4) 129 (33.9) 187 (33.0)
Overweight (25.0–29.9) 37 (20.0) 98 (25.7) 135 (23.9)
Obese (30.0–39.9) 51 (27.6) 98 (25.7) 149 (26.3)
Morbidly obese (40.0+) 11 (5.9) 20 (5.2) 31 (5.5)
Unknown 25 (13.5) 28 (7.3) 53 (9.4)
Long-standing conditions (mean, SD) 3.0 (1.8) 3.0 (1.8) 3.0 (1.8)
Long-standing conditions:
Yes 165 (89.2) 350 (91.9) 515 (91.0)
No 17 (9.2) 25 (6.6) 42 (7.4)
Unknown 3 (1.6) 6 (1.6) 9 (1.6)
Alcohol (units last week) (mean, SD) 7.0 (16.4) 7.7 (15.0) 7.4 (15.5)
Figures are frequencies (percentages) unless stated otherwise. PHQ Patient Health Questionnaire, GAD Generalised Anxiety Disorder, BMI body mass index
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favour of the offer group at 6 months of 1.5 points (95%
CI 0.5, 2.5, p = 0.003), with a small standardized effect
size in the offer group (Cohen’s d = 0.33). Results were
maintained at 12 months (ANCOVA: mean difference
1.6 points, 95% CI 0.6, 2.6, p = 0.002, Cohen’s d = 0.33).
For anxiety, secondary analyses varied somewhat more
than for depression outcomes, ranging from 1.0 to 1.5
points in favour of the offer group at 6 months, with
non-statistically significant results for 5 out of 15 tests,
and from 1.4 to 2.1 points at 12 months, with non-
statistically significant results for 6 out of 16 tests (details
in Additional files).
Effectiveness of treatment received
Depression outcomes and estimation
The primary IV analysis showed a mean between-
group difference in depression (PHQ-9) scores at
6 months of 2.6 points (95% CI 0.5, 4.7, p = 0.018)
in favour of patients who received treatment by a
homeopath, suggesting a moderate standardized effect
size (Cohen’s d = 0.57). Results were maintained at
12 months (mean difference 2.4 points, 95% CI 0.9,
4.0, p = 0.002, Cohen’s d = 0.53). Results of secondary
analyses at 6 and 12 months were comparable to the
main analyses and all results were statistically signifi-
cant (details in Additional files).
Anxiety outcomes and estimation
The primary IV analysis showed a mean between-group
difference in anxiety (GAD-7) scores at 6 months of 2.8
points (95% CI 0.9, 4.8, p = 0.004) in favour of patients
who received treatment by a homeopath, suggesting a
moderate standardized effect size (Cohen’s d = 0.61).
Results were maintained at 12 months (mean difference
2.8 points, 95% CI 1.4, 4.2, p = 0.000, Cohen’s d = 0.59).
Results of secondary analyses at 6 and 12 months
were comparable to the main analyses, although one
of the 16 tests was not statistically significant (details
in Additional files).
Adverse events and risks
Two researchers categorised 14 adverse events in 12
patients (16.2% of all treated patients in the offer
group) as certain (n = 1), probable/likely (n = 7), or pos-
sibly (n = 6) to be related to the intervention. Most
adverse events were mild (n = 11). Two events (in one
patient) were categorised as severe, as the patient
described them as “severe headache” and “severe pain
in chest, back, neck and jaw”. The events were transient
and were considered by the researchers to be only pos-
sibly related to the intervention as medical/hospital
exams did not reveal pathological conditions and the
symptoms did not return on repeating the homeopathic
medication (re-challenge). An aggravation of chronic
Table 3 Baseline medication and treatment
Baseline health measures Offer group (n = 185) No offer group (n = 381) Total (n = 566)
Antidepressant use (current):
Yes 81 (43.8) 155 (40.7) 236 (41.7)
No 0 (0.0) 1 (0.3) 1 (0.2)
Unknown 104 (56.2) 255 (59.1) 329 (58.1)
Antidepressant use (past):
Yes 103 (55.7) 234 (61.4) 337 (59.5)
No 53 (28.6) 124 (32.5) 177 (31.3)
Unknown 29 (15.7) 23 (6.0) 52 (9.2)
Medication (current, all types) (mean, SD) 4.7 (4.0) 4.7 (3.9) 4.7 (3.9)
Visits last 3 months (mean, SD):
Hospital (accident & emergency) 0.5 (1.6) 0.4 (0.6) 0.4 (1.0)
Hospital (day case) 0.5 (1.6) 0.4 (0.9) 0.4 (1.2)
Hospital (out-patient) 1.4 (2.5) 1.2 (2.0) 1.3 (2.2)
Hospital (in-patient nights) 0.6 (2.2) 0.8 (2.9) 0.8 (2.7)
General Practitioner 3.0 (5.6) 2.5 (2.4) 2.6 (3.8)
Nurse 1.9 (6.2) 1.4 (2.4) 1.6 (4.0)
Physiotherapist 1.0 (2.6) 0.6 (1.8) 0.8 (2.1)
Othera 1.9 (9.3) 1.2 (3.8) 1.4 (6.2)
Figures are frequencies (percentages) unless stated otherwise. aSummary including dietitian, midwife, mental health worker, psychotherapist, counsellor, care
worker, social worker, health visitor, community health champion, health trainer, acupuncturist, chiropractor, herbalist, osteopath (homeopath was 0 for both
groups, as prior use was an exclusion criterion)
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pain lasting for 3 weeks in another patient was categorised
as a moderate adverse event, but only possibly related to
the intervention, as it did not return on re-challenge. The
only adverse event considered to be certain to be related
to the intervention was the bad odour/taste of a homeo-
pathic medication (confirmed by the homeopath). The
manufacturer suggested it might be due to the medication
being past its expiry date. Another 10 adverse events were
unclassified (n = 1) or considered unlikely (n = 9) to be re-
lated to the intervention.
In addition, potential risk was considered in 58
patients (10.2%), with 36 in the no offer group (9.4%)
and 22 in the offer group (11.9%). Most patients (n = 55)
were considered to be at potential risk as they reported
not using antidepressants and indicating on a follow-up
questionnaire that they had thoughts nearly every day of
being better off dead or of hurting themselves. Patients
were contacted by telephone for further risk assessment
and their GPs were notified when patients could not be
reached. No serious adverse events are known to have
occurred in any of these patients.
Discussion
This was the first pragmatic randomised controlled trial
assessing the effectiveness of treatment provided by
homeopaths for depressed patients. The statistical ana-
lysis plan for the trial stated that a standardized effect
size would be used for assessing the clinical importance
of the results and these results suggest a small clinical
effect of the offer of treatment and a moderate effect of
treatment received by patients. However, there is some
evidence to suggest that the threshold level for the min-
imal clinically important difference (MCID) for PHQ-9
is a reduction of 5 points [29], which is more than the
score detected in this trial. Although wide confidence
intervals preclude any firm conclusions from being
drawn, these results warrant further research into this
intervention for depressed patients for three reasons.
First, existing interventions for depression are also
mostly associated with small effect sizes, e.g. anti-
depressants and psychological interventions with small
to moderate effect sizes [30, 31]. Although some trials
of psychotherapeutic interventions suggest moderate
to large effect sizes, most have unknown or high risk
of bias, and only smaller effects are seen when con-
trolling for unpublished trials or assessing higher
quality studies with larger sample sizes [30, 32].
Second, the results of this trial must be seen in
light of the fact that the majority of patients suffered
from long-standing depression and several comorbidi-
ties, and they are therefore harder to treat and have a
poorer prognosis [33].
Third, although this trial was not powered to detect
side-effects, no evidence suggested the treatment was
unsafe. Antidepressants are commonly associated with
risk of unwanted side-effects, some of which may be se-
vere and under-reported, and some argue that the harms
of antidepressants may outweigh the benefits [34–36].
The trial over-recruited within 5 months, a good result
when seen in light of the fact that trials often struggle to
reach recruitment goals [37]. It was anticipated that a
large proportion of patients would decline the offer of
treatment as this was not a treatment-seeking population
– thus, patients were unaware of the possibility of being
offered the intervention before trial start in this trial
within a cohort design [20]. Potential non-acceptance of
an offer of treatment is a specific feature of the cmRCT
design that warrants particular attention when interpret-
ing trial results. Regular ITT analyses represent the effect
of an “offer” of treatment, although we do not suggest
there is an effect simply of being offered the interven-
tion. ITT analyses will “water down” any potential effect
of interventions in cmRCT trials with low acceptance or
compliance rates. Therefore, IV analysis should be
applied to test the effectiveness of the received interven-
tion. Compared to “regular” RCTs, the use of the cmRCT
design provides the additional benefit of testing the
acceptability of the intervention. Treatment uptake in this
particular trial was good, given that this was not a clinical-
treatment-seeking population and the controversy sur-
rounding homeopathy in the UK over the past few years.
This was the first full trial of any intervention using
the cmRCT design. The benefits and challenges of using
this design of trials within a cohort (http://www.twics.
global) included full and fast recruitment, low attrition
and recruitment of a population reasonably similar to
the population of patients who self-report chronic depres-
sion (Viksveen P, Relton C, Nicholl J. Benefits and
challenges of using the “cohort multiple randomised con-
trolled trial” design for testing an intervention for depres-
sion. Trials. Forthcoming 2017 (accepted)).
A limitation of this trial was a lower 6-month and
12-month questionnaire response rate in patients who
were randomly selected to be offered the intervention,
but who did not take up the offer. There was, however,
no evidence to suggest that any baseline characteristics
were likely to significantly affect outcomes, so statistical
analyses of outcomes could be carried out with limited
risk of significant influence of known potential con-
founding due to differences in response rates. Another
limitation of this research was the lack of blinding of the
researcher who collected questionnaire responses and
carried out statistical analyses. Questionnaires were,
however, completed by patients at home, thereby avoid-
ing any undue research influence on patients, and data
management was checked by two other researchers.
This trial was not designed to answer the question of
whether or not homeopathic medicines are effective in
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treating depression, but whether treatment provided by
homeopaths for patients with self-reported depression is
effective. This treatment typically includes an initial
session lasting from one to two hours involving taking
history, clinical examination, discussion of treatment
options, and prescription of homeopathic medicines,
followed by up to ten sessions at monthly intervals to
review progress and adjust treatments. The pragmatic
nature of this trial; with recruitment of patients from a
large population-based health cohort, wide inclusion
criteria and encouraging practitioners to practise as they
normally do, increased the generalisability of results to
the general population of patients suffering from long-
standing self-reported depression who take up an offer
of treatment provided by a homeopath. Research ques-
tions that need further consideration if results of this
trial were to be reproduced include an understanding of
the mechanism of action, the effect of homeopathic
medicines and of the homeopath-patient interaction,
and indirect effects that may influence outcomes (e.g.
changes in patients’ medication).
Conclusion
An offer of treatment provided by homeopaths for
patients with self-reported depression was associated
with a small treatment effect over a time period of 6 to
12 months, whereas a moderate effect was found in
patients who received treatment. However, wide confi-
dence intervals preclude any firm conclusions from
being drawn. Further research should be conducted in
order to see if these findings can be replicated, and to
determine the safety of this adjunctive treatment.
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